Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stacey M Fernandes

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Nature|December 28, 2020
Mechanism of EBV inducing anti-tumour immunity and its therapeutic useIl-Kyu Choi, Zhe Wang, Qiang Ke, et al.
Leukemia|June 23, 2025
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemiaKiyomi Mashima, Yanan Kuang, Stacey M Fernandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
Rare Germline <i>ATM</i> Variants Influence the Development of Chronic Lymphocytic LeukemiaBenjamin L Lampson, Aditi Gupta, Svitlana Tyekucheva, et al.
Blood Cancer Journal|February 2, 2023
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitorsDeepti Gadi, Stephen P Martindale, Pui Yan Chiu, et al.
Cancer Cell|December 4, 2018
Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic LeukemiaChristopher J Ott, Alexander J Federation, Logan S Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2022
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic LeukemiaYanping Yin, Paschalis Athanasiadis, Linda Karlsen, et al.
Leukemia & Lymphoma|October 17, 2018
Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia<sup>.</sup>Matthew S Davids, Haesook T Kim, Lijian Yu, et al.
Haematologica|June 19, 2025
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignanciesBinu Kandathilparambil Sasi, Chiara Tarantelli, Stephen Martindale, et al.
Blood|July 17, 2012
LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomasYong Zhang, Aldo M Roccaro, Christopher Rombaoa, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
CCL19⁺ fibroblasts define a proliferative niche in chronic lymphocytic leukemiaAntonio P Ferreira, Shumei Wang, Larysa Poluben, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Nature|December 28, 2020
Mechanism of EBV inducing anti-tumour immunity and its therapeutic useIl-Kyu Choi, Zhe Wang, Qiang Ke, et al.
Leukemia|June 23, 2025
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemiaKiyomi Mashima, Yanan Kuang, Stacey M Fernandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
Rare Germline <i>ATM</i> Variants Influence the Development of Chronic Lymphocytic LeukemiaBenjamin L Lampson, Aditi Gupta, Svitlana Tyekucheva, et al.
Blood Cancer Journal|February 2, 2023
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitorsDeepti Gadi, Stephen P Martindale, Pui Yan Chiu, et al.
Cancer Cell|December 4, 2018
Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic LeukemiaChristopher J Ott, Alexander J Federation, Logan S Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2022
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic LeukemiaYanping Yin, Paschalis Athanasiadis, Linda Karlsen, et al.
Leukemia & Lymphoma|October 17, 2018
Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia<sup>.</sup>Matthew S Davids, Haesook T Kim, Lijian Yu, et al.
Haematologica|June 19, 2025
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignanciesBinu Kandathilparambil Sasi, Chiara Tarantelli, Stephen Martindale, et al.
Blood|July 17, 2012
LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomasYong Zhang, Aldo M Roccaro, Christopher Rombaoa, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
CCL19⁺ fibroblasts define a proliferative niche in chronic lymphocytic leukemiaAntonio P Ferreira, Shumei Wang, Larysa Poluben, et al.
Pageof 6